p53 and bcl-2 protein expression in non-small-cell lung carcinoma

被引:0
作者
Athanassiadou, P [1 ]
Dosios, T [1 ]
Petrakakou, E [1 ]
Liossi, A [1 ]
Zerva, C [1 ]
Athanassiades, P [1 ]
机构
[1] Sch Med, Dept Cytol, Pathol Lab, GR-11527 Athens, Greece
关键词
p53; bcl-2; non-small-cell lung carcinoma; immunocytochemistry;
D O I
10.1002/(SICI)1097-0339(199810)19:4<255::AID-DC5>3.0.CO;2-9
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The diagnostic significance of p53 and bcl-2 proteins in epithelial non-small-cell lung cancers was examined and the relationship between these proteins expression and other disease parameters, including stage of the disease and turner differentiation, were studied. We analyzed p53 and bcl-2 proteins expression irt 60 imprint smears of freshly resected lung tumors (37 squamous and 23 adenocarcinomas) using the immunocytochemical technique. There were seven patients with stage I disease, 24 with stage II, 23 with stage IIIa, and six with stage IIIb disease, according to the International Staging System classification Sixteen of the turners were bcl-2 positive and 25 were p53 positive, Twenty tumors were negative for both bcl-2 and p53 (33.3%). Statistical analysis showed no association between the incidence of p53 or bcl-2 positivity. Adenocarcinoma or squamous carcinoma analysis showed significant associations between p53 positivity and poor differentiation and advanced disease stage as well as bcl-2 and early disease stage and well-differentiated tumors. There was also an association between the stage of the disease and the degree of differentiation of the tumors. In conclusion, bcl-2 positivity must be considered a good prognostic sign. On the other hand p53 positivity seems to indicate, even in tumors at a relatively early stage, that a serious aggressive tumor which will not be easily eradicated is present (C) 1998 Wiley-Liss, Inc.
引用
收藏
页码:255 / 259
页数:5
相关论文
共 21 条
[1]   EVALUATION OF 6 ANTIBODIES FOR IMMUNOHISTOCHEMISTRY OF MUTANT P53 GENE-PRODUCT IN ARCHIVAL COLORECTAL NEOPLASMS [J].
BAAS, IO ;
MULDER, JWR ;
OFFERHAUS, GJA ;
VOGELSTEIN, B ;
HAMILTON, SR .
JOURNAL OF PATHOLOGY, 1994, 172 (01) :5-12
[2]   P53 in squamous metaplasia: A marker for risk of respiratory tract carcinoma [J].
Boers, JE ;
TenVelde, GPM ;
Thunnissen, FBJM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (01) :411-416
[3]   P53 SWEEPS THROUGH CANCER-RESEARCH [J].
CULOTTA, E ;
KOSHLAND, DE .
SCIENCE, 1993, 262 (5142) :1958-1961
[4]   MICE DEFICIENT FOR P53 ARE DEVELOPMENTALLY NORMAL BUT SUSCEPTIBLE TO SPONTANEOUS TUMORS [J].
DONEHOWER, LA ;
HARVEY, M ;
SLAGLE, BL ;
MCARTHUR, MJ ;
MONTGOMERY, CA ;
BUTEL, JS ;
BRADLEY, A .
NATURE, 1992, 356 (6366) :215-221
[5]   Apoptosis - Its role in tumour growth and therapy [J].
Ellis, PA ;
Smith, IE ;
Dowsett, M .
CYTOPATHOLOGY, 1996, 7 (03) :201-203
[6]  
GOTZ C, 1995, INT J ONCOL, V6, P1129
[7]   P53 - AT THE CROSSROADS OF MOLECULAR CARCINOGENESIS AND RISK ASSESSMENT [J].
HARRIS, CC .
SCIENCE, 1993, 262 (5142) :1980-1981
[8]   APOPTOSIS INDUCED BY ANTICANCER DRUGS [J].
HICKMAN, JA .
CANCER AND METASTASIS REVIEWS, 1992, 11 (02) :121-139
[9]   BCL-2 IS AN INNER MITOCHONDRIAL-MEMBRANE PROTEIN THAT BLOCKS PROGRAMMED CELL-DEATH [J].
HOCKENBERY, D ;
NUNEZ, G ;
MILLIMAN, C ;
SCHREIBER, RD ;
KORSMEYER, SJ .
NATURE, 1990, 348 (6299) :334-336
[10]  
KASTAN MB, 1991, CANCER RES, V51, P6304